Back to Search Results

New-Onset Diabetes Mellitus in COVID-19: A Scoping Review.

Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 020021, Bucharest, Romania. Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 020021, Bucharest, Romania. ioana-cristina.bica@drd.umfcd.ro. Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates. Medical Research Center, Sultan Qaboos University, Muscat, Oman. Department of Training and Studies, Royal Hospital, Ministry of Health, Muscat, Oman. Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland. Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland. Department of Biochemistry, Mohamed Bin Rashid University, Dubai, United Arab Emirates. IRCCS MultiMedica, Milan, Italy. Clinic of Endocrinology, Ankara Güven Hospital, Ankara, Turkey. Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, University of Stockholm, Stockholm, Sweden. Unit of Research and International Cooperation, University Hospital of Palermo, Palermo, Italy. Department of Biomedicine, Neurosciences and Advanced Diagnostics (Bind), University of Palermo, Palermo, Italy. Department of Endocrinology, Singapore General Hospital, Singapore, Singapore. Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia. Department of Endocrinology, Bharti Hospital and Bride, Karnal, India. Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India. Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. Department of Medicine and Oncology, Semmelweis University, Budapest, Hungary. The Research Institute, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates. Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo, Sao Paulo, Brazil. Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK. Dental Institute, Periodontology Unit, Centre for Host-Microbiome Interactions, King's College London, London, UK. Diabetes Center, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece. Social Determinants of Obesity and Cardiovascular Risk Laboratory, Cardiovascular Branch, Division of Intramural Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sci-Ences, Mashhad, Iran. Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil. Hospital Israelita Albert Einstein, Sao Paulo, Brazil. Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medi-Cine, Baltimore, MD, USA. Diabetes Research Centre, Chennai, India. Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMise), School of Medicine, University of Palermo, Palermo, Italy.

Diabetes therapy : research, treatment and education of diabetes and related disorders. 2024;(1):33-60
Full text from:

Other resources

Abstract

INTRODUCTION The coronavirus disease 2019 (COVID-19) pandemic became superimposed on the pre-existing obesity and diabetes mellitus (DM) pandemics. Since COVID-19 infection alters the metabolic equilibrium, it may induce pathophysiologic mechanisms that potentiate new-onset DM, and we evaluated this issue. METHOD A systematic review of the literature published from the 1 January 2020 until the 20 July 2023 was performed (PROSPERO registration number CRD42022341638). We included only full-text articles of both human clinical and randomized controlled trials published in English and enrolling adults (age > 18 years old) with ongoing or preceding COVID-19 in whom hyperglycemia was detected. The search was based on the following criteria: "(new-onset diabetes mellitus OR new-onset DM) AND (COVID-19) AND adults". RESULTS Articles on MEDLINE (n = 70) and the Web of Science database (n = 16) were included and analyzed by two researchers who selected 20 relevant articles. We found evidence of a bidirectional relationship between COVID-19 and DM. CONCLUSIONS This link operates as a pathophysiological mechanism supported by epidemiological data and also by the clinical and biological findings obtained from the affected individuals. The COVID-19 pandemic raised the incidence of DM through different pathophysiological and psychosocial factors.

Methodological quality

Publication Type : Review

Metadata